Local immunotherapy of cancer with interleukin 2

1989 ◽  
Vol 21 (4) ◽  
pp. 267-273 ◽  
Author(s):  
Jan Bubeník
1993 ◽  
Vol 119 (5) ◽  
pp. 253-256 ◽  
Author(s):  
J. Bubeník ◽  
J. Šímová ◽  
D. Bubeníková ◽  
J. Zeuthen ◽  
C. Radzikowski

2018 ◽  
Vol 99 (4) ◽  
pp. 593-597
Author(s):  
S Z Aliev

Aim. Study of the main cytokines (interleukin-1β and -2, interferon γ) in the mixed saliva from patients with chronic sialadenitis on the basic and comprehensive treatment dynamically. Methods. During the period of 2014 to 2017 we performed examination and treatment of patients with salivary gland diseases. Out of them we defined a group with chronic non-specific sialadenitis including 45 patients seen in the clinic in exacerbation. Patients in the comparison group received basic treatment. Patients in the study group additionally to conventional treatment were administered local immunotherapy. Measurement of cytokine levels in the oral fluid was performed in 45 patients with chronic sialadenitis in exacerbation and in 10 practically healthy subjects. Results. The level of interleukin-1β in saliva was found to be significantly increased before treatment (p <0.05). After the treatment interleukin-1β level in saliva decreased in both groups but most significantly this parameter decreased in the study group. After including local immunocorrection into the treatment complex dynamic decrease of interleukin-2 to 14.7±0.4 pg/ml was registered, which apparently is associated with stabilization of immune processes in the oral cavity. After the treatment conducted according to traditional scheme in the comparison group the level of interferon γ in saliva increased to 7.2±0.2 pg/ml which is 1.1 times higher than before treatment. Conclusion. In patients with chronic sialadenitis in exacerbation the level of interleukin-1β statistically significantly increases by 1. times (p <0.05), interleukin 2 - by 2.1 times (p <0.05) and the level of interferon γ decreases by 1.4 times (p <0.05) which is indicative of immunological signs of inflammatory reaction; use of local immunocorrection leads to more prominent decrease of interleukin-1β (by 20.3 vs 16.2% in comparison group; p <0.05), interleukin-2 (by 38.8 vs 26.6%; p <0.05) and increase of interferon γ (by 21.2 vs 12.5% in comparison group; p <0.05).


Gene Therapy ◽  
2003 ◽  
Vol 10 (26) ◽  
pp. 2126-2132 ◽  
Author(s):  
T-M Jourdier ◽  
C Moste ◽  
M-C Bonnet ◽  
F Delisle ◽  
J-P Tafani ◽  
...  

1995 ◽  
Vol 10 (2) ◽  
pp. 124-125 ◽  
Author(s):  
P. Lissoni ◽  
V. Arosio ◽  
E. Mocchegiani ◽  
N. Fabris ◽  
S. Barni ◽  
...  

1988 ◽  
Vol 74 (5) ◽  
pp. 523-530 ◽  
Author(s):  
Carlo Gambacorti-Passerini ◽  
Marina Radrizzani ◽  
Licia Rivoltini ◽  
Edoardo Marchesi ◽  
Fernando Ravagnani ◽  
...  

A new procedure for activation of peripheral blood lymphocytes (PBL) with recombinant interleukin 2 (rIL2) is described. PBL obtained by leukapheresis were subjected to NH4Cl (ACK) treatment to clear erythrocyte contamination; Ficoll separation was not performed. PBL were subsequently seeded in 10-floor multitrays (Cell Factory™, CF), gasified and incubated at 37 °C for 3-4 days in a humidified 5% CO2 atmosphere. This procedure achieved an activation (evaluated as cytotoxicity and proliferation) comparable with that obtained by culturing PBL in small flasks. Optimal activation of PBL was achieved in CF even in the presence of granulocyte contamination of up to 40%. It was also possible to freeze, thaw and recover most of the frozen cells and their cytotoxic activity. With this procedure therefore large quantities of lymphokine activated killer cells (LAK) can be easily produced to be used in adoptive immunotherapy trials.


1993 ◽  
Vol 29 (8) ◽  
pp. 1127-1132 ◽  
Author(s):  
P. Lissoni ◽  
S. Barni ◽  
F. Rovelli ◽  
S. Pittalis ◽  
A. Ardizzoia ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document